Year: 2020

SALISBURY, Md., Nov. 12, 2020 (GLOBE NEWSWIRE) — Partners Bancorp (NASDAQ: PTRS) (the “Company”), the parent company of The Bank of Delmarva (“Delmarva”), Seaford, Delaware, and Virginia Partners Bank (“Virginia Partners”), Fredericksburg, Virginia, announced today that its Board of Directors has approved a stock purchase plan. Under the plan, the Company is authorized to purchase up to 356,000 outstanding shares of its common stock. The Company may repurchase shares in the open market or through privately negotiated transactions.Lloyd B. Harrison, III, the Company’s Chief Executive Officer, commented, “We consider this to be in the best interests of the Company as it may be expected to improve the Company’s operating performance on a per share basis and enhance, in the long term, the market price per share of the Company’s common...

CHIHUAHUA, Mexico, Nov. 12, 2020 (GLOBE NEWSWIRE) — Grupo Cementos de Chihuahua, S.A.B. de C.V. (BMV: GCC*, or “the Company”), a leading producer of cement and concrete in the United States and Mexico, announced today that it has obtained a favorable resolution in the annulment of the “Damages Award”, in the arbitration process commenced by Compañía de Inversiones Mercantiles, S.A. (“CIMSA”), against the Company and pursuant to the Inter-American Commission on International Commercial Arbitration.This annulment was notified by the highest constitutional justice authority in Bolivia on October 29th of this year. Consequently, all legal proceedings filed in the country of Bolivia have been resolved in favor of GCC.Based on this resolution, the Company will commence the corresponding legal proceedings in the United States to reverse...

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming Canaccord Genuity Virtual MedTech & Diagnostics Forum.Management is scheduled to present Thursday, November 19, 2020 at 2:30pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com.About T2 BiosystemsT2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel,...

Increasing Placebo Responses in PTSD Drug Trials Raise Questions About Current Methods of Measuring or Analyzing PTSD Symptom Change Over TimeThe U.S. 21st Century Cures Act Provides Direction on New Statistical Analyses Using SimulationsTonix Plans to Study TNX-102 SL in a New Phase 3 PTSD Trial in KenyaCHATHAM, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, outlined a new statistical method to analyze future Posttraumatic Stress Disorder (PTSD) drug studies and presented a retrospective analysis using the new method of the Phase 3 HONOR study (P301) of TNX-102 SL (cyclobenzaprine HCl sublingual tablets), for the treatment...

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients with sickle cell disease. Mitapivat is an investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes.“Receiving orphan drug designation for mitapivat in sickle cell disease is an important recognition of the tremendous unmet need among this patient community, which has historically been underserved,” said Chris Bowden, M.D., chief medical officer at Agios. “As the pioneers in PKR activation, we believe...

SAN RAMON, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — CooperCompanies (NYSE: COO) announced today that its Board of Directors elected Teresa S. Madden to the Board as an independent director, effective December 1, 2020.“We are delighted to have Teresa join our Board of Directors,” said Al White, President and CEO. “Teresa brings a unique perspective that combines operational excellence and financial acumen, with long-term experience in an industry that was continually being pushed to evolve and change. We look forward to Teresa’s advice and support as Cooper continues growing its business.”Ms. Madden is an independent director of Enbridge, Inc. (NYSE: ENB) where she serves on the governance committee and as chair of the audit, finance and risk committee. She previously served as a director of Peabody Energy Corporation (NYSE: BTU)...

SAN FRANCISCO, Nov. 12, 2020 (GLOBE NEWSWIRE) — 5:01 Acquisition Corp. (the “Company”) (NASDAQ: FVAM) announced today that the underwriter of its previously announced initial public offering of Class A common stock, par value $0.0001 per share, partially exercised its over-allotment option resulting in the issuance of an additional 256,273 shares at a price to the public of $10.00 per share for gross proceeds of approximately $2.6 million.The Company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.The Company’s shares of Class A common stock began trading on The Nasdaq Capital Market under the ticker symbol “FVAM” on October 14, 2020.BofA Securities acted as sole book-running manager...

FOSTER CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the third quarter ended September 30, 2020 and provided a business update.“Vaxcyte continues to make steady progress in executing on our business objectives,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “We advanced several important manufacturing activities for VAX-24, our 24-valent investigational pneumococcal conjugate vaccine, or PCV, designed to prevent invasive pneumococcal disease, as we proceed toward our anticipated IND filing in the second half of next year....